IS7805A - Drying process - Google Patents

Drying process

Info

Publication number
IS7805A
IS7805A IS7805A IS7805A IS7805A IS 7805 A IS7805 A IS 7805A IS 7805 A IS7805 A IS 7805A IS 7805 A IS7805 A IS 7805A IS 7805 A IS7805 A IS 7805A
Authority
IS
Iceland
Prior art keywords
drying process
drying
Prior art date
Application number
IS7805A
Other languages
Icelandic (is)
Other versions
IS3028B (en
Inventor
Mayeresse Yves
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7805(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0225543A external-priority patent/GB0225543D0/en
Priority claimed from GBGB0225520.6A external-priority patent/GB0225520D0/en
Priority claimed from GB0225532A external-priority patent/GB0225532D0/en
Priority claimed from GB0317381A external-priority patent/GB0317381D0/en
Priority claimed from GB0317371A external-priority patent/GB0317371D0/en
Priority claimed from GB0317380A external-priority patent/GB0317380D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of IS7805A publication Critical patent/IS7805A/en
Publication of IS3028B publication Critical patent/IS3028B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IS7805A 2002-11-01 2005-04-18 Drying method IS3028B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0225543A GB0225543D0 (en) 2002-11-01 2002-11-01 Immunogenic composition
GBGB0225520.6A GB0225520D0 (en) 2002-11-01 2002-11-01 Drying process
GB0225532A GB0225532D0 (en) 2002-11-01 2002-11-01 Drying process
GB0317381A GB0317381D0 (en) 2003-07-24 2003-07-24 Drying method
GB0317371A GB0317371D0 (en) 2003-07-24 2003-07-24 Immunogenic composition
GB0317380A GB0317380D0 (en) 2003-07-24 2003-07-24 Drying method

Publications (2)

Publication Number Publication Date
IS7805A true IS7805A (en) 2005-04-18
IS3028B IS3028B (en) 2021-05-15

Family

ID=32234471

Family Applications (2)

Application Number Title Priority Date Filing Date
IS7806A IS7806A (en) 2002-11-01 2005-04-18 Immunogenic composition
IS7805A IS3028B (en) 2002-11-01 2005-04-18 Drying method

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS7806A IS7806A (en) 2002-11-01 2005-04-18 Immunogenic composition

Country Status (28)

Country Link
US (3) US7927858B2 (en)
EP (3) EP1556477B1 (en)
JP (2) JP4579156B2 (en)
KR (2) KR101058978B1 (en)
AR (2) AR041881A1 (en)
AT (1) ATE352316T1 (en)
AU (2) AU2003278166B2 (en)
BR (1) BR0315767A (en)
CA (2) CA2503946C (en)
CY (2) CY1119362T1 (en)
DE (1) DE60311526T2 (en)
DK (2) DK2395073T3 (en)
ES (3) ES2649048T3 (en)
HK (1) HK1085380A1 (en)
HU (1) HUE034801T2 (en)
IL (2) IL168052A (en)
IS (2) IS7806A (en)
LT (2) LT2395073T (en)
MA (2) MA27644A1 (en)
MX (3) MXPA05004675A (en)
MY (2) MY132859A (en)
NO (3) NO20052010L (en)
NZ (2) NZ539706A (en)
PL (2) PL213647B1 (en)
PT (2) PT2395073T (en)
SI (2) SI2395073T1 (en)
TW (2) TWI332843B (en)
WO (2) WO2004039417A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132859A (en) * 2002-11-01 2007-10-31 Glaxosmithkline Biologicals Sa Immunogenic composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
AU2005245338B2 (en) * 2004-04-08 2011-11-17 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
TWI398272B (en) * 2005-03-08 2013-06-11 Intervet Int Bv Chemically defined stabiliser
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
ATE516816T1 (en) 2005-06-27 2011-08-15 Glaxosmithkline Biolog Sa METHOD FOR PRODUCING VACCINES
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
PT2097102E (en) 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Combination vaccine having reduced polio virus antigen quantities
CA2673120C (en) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation A dry food product containing live probiotic
EA200901340A1 (en) 2007-05-02 2010-04-30 Глаксосмитклайн Байолоджикалс С.А. VACCINE
KR101557169B1 (en) * 2007-05-18 2015-10-02 메디뮨 엘엘씨 Preservation of bioactive materials by freeze dried foam
US20100184059A1 (en) * 2007-06-16 2010-07-22 Enigma Diagnostics Limited Compositions
GB0711683D0 (en) * 2007-06-16 2007-07-25 Enigma Diagnostics Ltd Compositions
EP2182922A4 (en) * 2007-07-26 2010-07-28 Sanofi Pasteur Ltd Antigen-adjuvant compositions and methods
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
EP2435554B1 (en) 2009-05-26 2017-07-26 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
EP2475393A4 (en) * 2009-09-14 2013-08-21 Vu Truong-Le Formulation for room temperature stabilization of a live attenuated bacterial vaccine
WO2011094469A2 (en) 2010-01-28 2011-08-04 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
FR2960781B1 (en) * 2010-06-07 2013-11-22 Sanofi Pasteur PREPARATION OF STABILIZED DRY ORAL VACCINE COMPOSED OF ATTENUATED LIVE VIRUS
CA2806670A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
NZ607226A (en) 2010-08-13 2015-03-27 Advanced Bionutrition Corp Dry storage stabilizing composition for biological materials
BR112013005049A2 (en) 2010-09-02 2016-05-31 Sanofi Pasteur stabilizer for the preparation of an injectable dry polio vaccine composition
ES2630012T3 (en) 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Freeze-dried viral formulations
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
KR20140018966A (en) * 2011-04-07 2014-02-13 글락소스미스클라인 엘엘씨 Formulations with reduced viscosity
SG193964A1 (en) * 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity
US20120294894A1 (en) 2011-05-20 2012-11-22 Nitto Denko Corporation Pharmaceutical composition and method for producing the same
PE20191242A1 (en) 2011-10-25 2019-09-16 Prothena Biosciences Ltd ANTIBODY FORMULATIONS AND METHODS
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
CN105530955A (en) * 2013-10-03 2016-04-27 日东电工株式会社 Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation
CN105899220B (en) * 2013-12-19 2020-01-10 扬森疫苗与预防公司 Improved virosome formulations
KR20160119806A (en) 2014-02-11 2016-10-14 메사추세츠 인스티튜트 오브 테크놀로지 Novel full spectrum anti-dengue antibody
EP3942931A1 (en) 2014-06-10 2022-01-26 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
WO2016012385A1 (en) * 2014-07-21 2016-01-28 Sanofi Pasteur Vaccine composition comprising ipv and cyclodextrins
EP3328215B1 (en) 2015-07-29 2021-07-07 Advanced BioNutrition Corp. Stable dry probiotic compositions for special dietary uses
CN108472357A (en) * 2015-09-04 2018-08-31 创赏有限公司 The vaccine composition that VLP stablizes
KR20230145258A (en) 2015-12-08 2023-10-17 바이오매트리카 인코포레이티드 Reduction of erythrocyte sedimentation rate
EP4309670A2 (en) 2016-09-02 2024-01-24 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
AU2019254473A1 (en) * 2018-04-16 2020-12-03 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
CA3112902A1 (en) * 2018-09-28 2020-04-02 Otsuka Pharmaceutical Factory, Inc. Mammal cell preserving solution containing acarbose or stachyose

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509893A (en) * 1893-12-05 William griesser
DE1157734B (en) * 1961-08-16 1963-11-21 Behringwerke Ag Process for the production of stable, orally administered poliomyelitis virus preparations
US3767790A (en) 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US3929132A (en) * 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
GB8323094D0 (en) * 1983-08-26 1983-09-28 Franks F Preservation of cells
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
ATE68524T1 (en) 1985-07-09 1991-11-15 Quadrant Bioresources Ltd PROTECTION OF PROTEINS AND THE LIKE.
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
GB8715238D0 (en) 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
DE3819530A1 (en) * 1988-06-08 1989-12-21 Westphal Geb Jauch Christel Dr Process, carrier and test kit for the cultivation and microscopic examination of cells
HUT58804A (en) 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
JPH03161441A (en) 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk Maillard reaction inhibitor
DE69133276T2 (en) 1990-07-16 2003-11-27 Univ North Carolina ANTIGENT IRON-SUPPRESSING PROTEINS OF THE N. MENINGITIS RELATED TO THE HEMOLYSIN TOXINE FAMILY
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
CA2087958C (en) 1990-08-23 2007-05-15 P. Frederick Sparling Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
FR2682041B1 (en) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins VACCINE AGAINST NEISSERIA MENINGITIDIS INFECTIONS.
IT1253009B (en) 1991-12-31 1995-07-10 Sclavo Ricerca S R L DETOXIFIED IMMUNOGENIC MUTANTS OF COLERIC TOXIN AND TOXIN LT, THEIR PREPARATION AND USE FOR THE PREPARATION OF VACCINES
KR950700081A (en) 1992-02-11 1995-01-16 W 로우 죤 Dual Carrier Immunogenic Constructs
CA2383007A1 (en) 1992-03-02 1993-09-16 Chiron S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
UA40596C2 (en) 1992-05-23 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine formulation and method for its preparing
FR2692592B1 (en) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc DNA fragments encoding the Neisseria meningitidis transferrin receptor subunits and methods of expressing them.
SG47725A1 (en) 1992-10-27 1998-04-17 American Cyanamid Co Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
WO1994026304A1 (en) 1993-05-18 1994-11-24 Ohio State Research Foundation Otitis media vaccine
AU3191495A (en) * 1994-08-09 1996-03-07 Nisshin Oil Mills, Ltd., The Peroral immunogen composition and process for producing the same
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
IL122431A0 (en) 1995-06-07 1998-06-15 Smithkline Beecham Biolog Combined vaccine comprising a polysaccharide antigen conjugated to a carrier protein
AP852A (en) 1995-06-07 2000-06-16 Quadrant Holdings Cambridge Ltd Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby.
EA199800046A1 (en) 1995-06-07 1998-06-25 Байокем Вэксинс Инк. POLYPEPTIDE, DNA SEQUENCE, VACCINE COMPOSITION (OPTIONS), ANTIBODY OR ITS FRAGMENT, VACCINE, APPLICATIONS OF POLYPEPTIDE-INDICATED, DNA SEQUENCE AND ANTIBODY OR ITS FRAGMENT
PT833662E (en) 1995-06-23 2001-09-28 Smithkline Beecham Biolog A VACCINAL COMPOSITION UNDERSTANDING A CONJUGATED POLYSACARIDATE ANTIGEN ADOSORVED TO ALUMINUM PHOSPHATE
DE19543770C2 (en) 1995-11-24 1998-11-05 Metallgesellschaft Ag Device for measuring condensed moisture in devices and / or pipelines in chemical engineering and their use
AU1671197A (en) * 1996-02-13 1997-09-02 Nisshin Oil Mills, Ltd., The Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
ATE323721T1 (en) 1996-05-01 2006-05-15 Univ Rockefeller CHOLINE-BINDING PROTEIN USED AS AN PNEUMOCOCCAL VACCINE
US5766520A (en) 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
AU3214597A (en) * 1996-05-29 1998-01-05 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
RU2194531C2 (en) 1996-07-02 2002-12-20 Коннот Лабораториз Лимитед Polyvalent associated diphtheria, tetanus toxoids and pertussis poliovirus vaccines
FR2751000B1 (en) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med SPECIFIC DNA FROM NEISSERIA MENINGITIDIS BACTERIA, PROCESSES FOR OBTAINING THEM AND BIOLOGICAL APPLICATIONS
DE19630390A1 (en) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteins, in particular membrane proteins from Helicobacter pylori, their production and use
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
CA2269663A1 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
SE511963C2 (en) 1997-04-23 1999-12-20 Ericsson Telefon Ab L M Device and method for determining line voltage in a subscriber line circuit
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU740956B2 (en) 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1028750B1 (en) 1997-09-15 2006-02-01 Sanofi Pasteur MSD Method for preparing multivalent vaccines
ATE352624T1 (en) 1997-11-21 2007-02-15 Serono Genetics Inst Sa CHLAMYDIA PNEUMONIAE GENOMIC SEQUENCES AND POLYPEPTIDES, FRAGMENTS AND APPLICATIONS THEREOF FOR DETECTION, PREVENTION AND CURE
KR20010032550A (en) * 1997-11-26 2001-04-25 유니버설 프리저베이션 테크놀로지스 인코포레이티드 Preservation of Sensitive Biological Samples by Vitrification
KR100769104B1 (en) 1997-11-28 2007-10-23 세로노 제네틱스 인스티튜트 에스.에이. Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
WO1999051266A2 (en) 1998-04-07 1999-10-14 Medimmune, Inc. Derivatives of pneumococcal choline binding proteins for vaccines
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
EP1645631B1 (en) 1998-05-01 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Neisseria antigens and compositions
US6306345B1 (en) 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
CA2346713A1 (en) 1998-10-09 2000-04-20 Chiron Corporation Neisseria genomic sequences and methods of their use
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
PL355178A1 (en) 1999-03-19 2004-04-05 Smithkline Beecham Biologicals S.A. Vaccine
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
ATE400296T1 (en) 1999-12-02 2008-07-15 Novartis Vaccines & Diagnostic COMPOSITIONS AND METHODS FOR STABILIZING BIOLOGICAL MOLECULES AFTER LYOPHILIZATION
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
BR0108711A (en) 2000-02-28 2004-06-22 Chiron Spa Heterologous expression of neisserial proteins
AP1695A (en) 2000-06-29 2006-12-17 Glaxosmithkline Biologicals Sa Multivalent vaccine composition.
US20040005667A1 (en) 2000-07-03 2004-01-08 Giuloi Ratti Immunisation against chlamydia pneumoniae
KR100385711B1 (en) * 2000-07-05 2003-05-27 녹십자백신 주식회사 The quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis b surface antigen and the preparation thereof
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
CA2849556A1 (en) * 2002-04-11 2003-10-23 Vu Truong-Le Preservation of bioactive materials by freeze dried foam
MY132859A (en) 2002-11-01 2007-10-31 Glaxosmithkline Biologicals Sa Immunogenic composition
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
DE60311526T2 (en) 2007-10-31
PL376950A1 (en) 2006-01-09
JP2006504801A (en) 2006-02-09
US20110159038A1 (en) 2011-06-30
IL168052A0 (en) 2011-08-01
NO20052010D0 (en) 2005-04-25
PT1556477T (en) 2017-11-14
CA2503946A1 (en) 2004-05-13
EP2395073A3 (en) 2012-01-25
NO20051998D0 (en) 2005-04-25
EP1556477B1 (en) 2017-08-09
CA2503871C (en) 2012-12-11
US20060127414A1 (en) 2006-06-15
BR0315767A (en) 2005-09-06
SI2395073T1 (en) 2017-12-29
TW200501981A (en) 2005-01-16
KR101058978B1 (en) 2011-08-23
CY1119504T1 (en) 2018-03-07
NO20052010L (en) 2005-06-24
US8449865B2 (en) 2013-05-28
WO2004039417A3 (en) 2004-12-16
ATE352316T1 (en) 2007-02-15
MXPA05004675A (en) 2005-06-08
EP1575612B1 (en) 2007-01-24
ES2645924T3 (en) 2017-12-11
JP2006512406A (en) 2006-04-13
MXPA05004528A (en) 2005-07-26
NO344759B1 (en) 2020-04-14
NO20051998L (en) 2005-06-24
US8409587B2 (en) 2013-04-02
US7927858B2 (en) 2011-04-19
DK2395073T3 (en) 2017-10-23
TWI332843B (en) 2010-11-11
HUE034801T2 (en) 2018-02-28
IL168052A (en) 2015-03-31
US20060127415A1 (en) 2006-06-15
NZ539706A (en) 2008-03-28
WO2004039417A2 (en) 2004-05-13
CA2503871A1 (en) 2004-05-13
MY145693A (en) 2012-03-30
ES2649048T3 (en) 2018-01-09
MX343419B (en) 2016-11-04
PL377170A1 (en) 2006-01-23
EP2395073A2 (en) 2011-12-14
CA2503946C (en) 2016-08-16
IL168054A (en) 2011-06-30
DK1556477T3 (en) 2017-10-23
EP1556477A2 (en) 2005-07-27
NO20180874A1 (en) 2005-06-24
KR101130948B1 (en) 2012-03-30
TW200501980A (en) 2005-01-16
WO2004039399A1 (en) 2004-05-13
LT2395073T (en) 2017-11-10
CY1119362T1 (en) 2018-03-07
KR20050075766A (en) 2005-07-21
AU2003278166B2 (en) 2009-01-29
MA27644A1 (en) 2005-12-01
HK1085380A1 (en) 2006-08-25
LT1556477T (en) 2017-10-25
MY132859A (en) 2007-10-31
AR041881A1 (en) 2005-06-01
IS3028B (en) 2021-05-15
IS7806A (en) 2005-04-18
PL215237B1 (en) 2013-11-29
JP4579156B2 (en) 2010-11-10
AU2003278166A1 (en) 2004-05-25
AR041880A1 (en) 2005-06-01
EP2395073B1 (en) 2017-09-06
ES2280809T3 (en) 2007-09-16
MA27551A1 (en) 2005-10-03
AU2003287980A1 (en) 2004-05-25
NZ539613A (en) 2008-09-26
AU2003287980B2 (en) 2009-06-25
PL213647B1 (en) 2013-04-30
NO342741B1 (en) 2018-08-06
SI1556477T1 (en) 2017-12-29
DE60311526D1 (en) 2007-03-15
EP1575612A1 (en) 2005-09-21
PT2395073T (en) 2017-11-24
KR20050084626A (en) 2005-08-26

Similar Documents

Publication Publication Date Title
IS7805A (en) Drying process
DK1531673T3 (en) Hitherto unknown 2-pyridylethylbenzamide derivative
DE60212275D1 (en) Drier
DE50311534D1 (en) GEWEBEBAND SETUP
DE502004004375D1 (en) DRIER
DE60326724D1 (en) STRUCTURING PROCESS
FI20020479A (en) Coating Process
DE60227910D1 (en) clothes dryer
DE50302710D1 (en) clothes dryer
DE50203350D1 (en) printing process
FI20031304A0 (en) dryer
NO20041043L (en) Procedure for washing objects
DE60331878D1 (en) printing process
DE60209395D1 (en) Collection dryer
GB0225520D0 (en) Drying process
SE0201004D0 (en) New process
SE0202568D0 (en) New process
SE0201363D0 (en) Novel process
SE0202041D0 (en) Novel process
NO20043433L (en) Approach
ITMI20020305V0 (en) CLOTHES
FIU20020336U0 (en) drying Rack
UA6425S (en) DECORATIONS FOR CLOTHES
FI20031623A0 (en) Dry Process System
FI20031162A0 (en) Dry Process System